Pertussis continues to put New Zealand's immunisation strategy to the test

New Zealand Medical Journal

Volumn 123, Issue 1313, 2010, Pages 46-61

  Grant, Cameron C ^a,b   Reid, Stewart ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b STARSHIP CHILDREN S HOSPITAL   (New Zealand)

^c Ropata Medical Centre   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DT COQ; PERTUSSIS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CAUSE OF DEATH; CHILD; DRUG EFFICACY; DRUG INDICATION; HEALTH PROGRAM; HUMAN; INCIDENCE; INFECTION CONTROL; MASS IMMUNIZATION; NEW ZEALAND; PERTUSSIS; PREVENTIVE HEALTH SERVICE; PRIMARY PREVENTION; REPEATED DRUG DOSE;

HUMANS; IMMUNIZATION; IMMUNIZATION PROGRAMS; MORBIDITY; NEW ZEALAND; PERTUSSIS VACCINE; WHOOPING COUGH;

EID: 77951728555     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. Crowcroft NS, Pebody RG. Recent developments in pertussis. Lancet 2006;367:1926-1936
2. Crowcroft NS, Stein C, Duclos P, Birmingham M. How best to estimate the global burden of pertussis? Lancet Infect Dis 2003;3:413-418
3. Gordon JE, Aycock WL. Whooping cough and its epidemiological anomalies. Amer J Med Sci 1951;222:333-361
4. Van Buynder PG, Owen D, Vurdien JE, et al. Bordetella pertussis surveillance in England and Wales: 1995-7. Epidemiol Infect 1999;123:403-411
5. Crowcroft NS, Andrews N, Rooney C, et al. Deaths from pertussis are underestimated in England. Arch Dis Child 2002;86:336-338 (Pubitemid 34478227)
6. Sutter RW, Cochi SL. Pertussis hospitalizations and mortality in the United States, 1985-1988. Evaluation of the completeness of national reporting. JAMA 1992;267:386-391
7. Shaikh R, Guris D, Strebel PM, Wharton M. Underreporting of pertussis deaths in the United States: need for improved surveillance. Pediatrics 1998;101:323. (Pubitemid 28076674)
8. Halasa NB, Barr FE, Johnson JE, Edwards KM. Fatal pulmonary hypertension associated with pertussis in infants: does extracorporeal membrane oxygenation have a role? Pediatrics 2003;112:1274-1278
9. Mikelova LK, Halperin SA, Scheifele D, et al. Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. J Pediatr 2003;143:576-581 (Pubitemid 37452782)
10. McEniery JA, Delbridge RG, Reith DM. Infant pertussis deaths and the management of cardiovascular compromise. J Paediatr Child Health 2004;40:230-232
11. Fine PE, Clarkson JA. Seasonal influences on pertussis. Int J Epidemiol 1986;15:237-247
12. Luttinger P. The epidemiology of pertussis. Amer J Dis Child 1916;12:290-315.
13. Mannerstedt G. Pertussis in adults. J Pediatr 1934;5:596-600.
14. Farizo KM, Cochi SL, Zell ER, et al. Epidemiological features of pertussis in the United States, 1980-1989. Clin Infect Dis 1992;14:708-719
15. Guris D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999;28:1230-1237
16. Provenzano RW, Wetterlow LH, Sullivan CL. Pertussis immunization in pediatric practice and in public health. N Eng J Med 1959;261:473-478
17. Cortese MM, Baughman AL, Zhang R, et al. Pertussis hospitalizations among infants in the United States, 1993 to 2004. Pediatrics 2008;121:484-492
18. Cherry JD. Epidemiological, clinical, and laboratory aspects of pertussis in adults. Clin Infect Dis 1999;28:S112-7.
19. Harnden A, Grant C, Harrison T, et al. Whooping cough in school age children with persistent cough: prospective cohort study in primary care. BMJ 2006;333:174-177. (Pubitemid 44406743)
20. Thomas MG. Epidemiology of pertussis. Rev Infect Dis 1989;11:255-262
21. Fine PE. Herd immunity: history, theory, practice. Epidemiol Rev 1993;15:265-302.
22. Long SS, Welkon CJ, Clark JL. Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. J Infect Dis 1990;161:480-486
23. Mertsola J, Ruuskanen O, Eerola E, Viljanen MK. Intrafamilial spread of pertussis. J Pediatr 1983;103:359-363
24. De Schutter I, Malfroot A, Dab I, et al. Molecular typing of Bordetella pertussis isolates recovered from Belgian children and their household members. Clin Infect Dis 2003;36:1391-1396 (Pubitemid 36702872)
25. Anderson RM, May RM. Directly transmitted infections diseases: control by vaccination. Science 1982;215:1053-1060
26. Fine PE, Clarkson JA. The recurrence of whooping cough: possible implications for assessment of vaccine efficacy. Lancet 1982;1:666-669
27. Somerville RL, Grant CC, Scragg RK, Thomas MG. Hospitalisations due to pertussis in New Zealand in the pre-immunisation and mass immunisation eras. J Paediatr Child Health 2007;43:147-153
28. Miller E, Gay NJ. Epidemiological determinants of pertussis. Dev Biol Stand 1997;89:15-23.
29. Wirsing von Konig CH, Postels Multani S, Bock HL, Schmitt HJ. Pertussis in adults: frequency of transmission after household exposure. Lancet 1995;346:1326-1329
30. Surridge J, Segedin ER, Grant CC. Pertussis requiring intensive care. Arch Dis Child 2007;92:970-975
31. Centers for Disease Control and Prevention (US). Guidelines for the Control of Pertussis Outbreaks. Atlanta (GA): Centers for Disease Control and Prevention, 2000.
32. Biellik RJ, Patriarca PA, Mullen JR, et al. Risk factors for community- and householdacquired pertussis during a large-scale outbreak in central Wisconsin. J Infect Dis 1988;157:1134-1141
33. Joo I. Epidemiology of pertussis in Hungary. Dev Biol Stand 1991;73:357-359
34. Finger H, Wirsing von Konig CH, Tacken A, Wassilak SG. The epidemiological situation of pertussis in the Federal Republic of Germany. Dev Biol Stand 1991;73:343-355
35. Romanus V, Jonsell R, Bergquist SO. Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr Infect Dis J 1987;6:364-371
36. Anonymous. Pertussis - England and Wales. MMWR - Morb Mortal Wkly Rep 1982;31:629-632
37. Miller E, Vurdien JE, White JM. The epidemiology of pertussis in England and Wales. Commun Dis Rep CDR Review 1992;2:R152-4.
38. de Melker HE, Schellekens JF, Neppelenbroek SE, et al. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis 2000;6:348-357
39. White JM, Fairley CK, Owen D, et al. The effect of an accelerated immunisation schedule on pertussis in England and Wales. Commun Dis Rep CDR Review 1996;6:R86-91.
40. Noble GR, Bernier RH, Esber EC, et al. Acellular and whole-cell pertussis vaccines in Japan. Report of a visit by US scientists. JAMA 1987;257:1351-1356
41. Kimura M, Kuno-Sakai H. Developments in pertussis immunisation in Japan. Lancet 1990;336:30-32
42. De Serres G, Boulianne N, Duval B, et al. Effectiveness of a whole cell pertussis vaccine in child-care centers and schools. Pediatr Infect Dis J 1996;15:519-524 (Pubitemid 26187797)
43. Mooi FR, He Q, van Oirschot H, Mertsola J. Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland. Infect Immun 1999;67:3133-3134 (Pubitemid 29244740)
44. World Health Organization. Report of the WHO meeting on case definitions of pertussis. Geneva: World Health Organization, 1991.
45. Liese JG, Meschievitz CK, Harzer E, et al. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr Infect Dis J 1997;16:1038-1044 (Pubitemid 27494960)
46. Stehr K, Cherry J, Heininger U, et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics 1998;101:1-11. (Pubitemid 28030315)
47. Simondon F, Preziosi MP, Yam A, et al. A randomized double-blind trial comparing a twocomponent acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997;15:1606-1612 (Pubitemid 27445741)
48. Anonymous. Pertussis vaccines - WHO position paper. Weekly Epidemiological Record 2005;80:31-39
49. Bourchier D, Abbott GD, Fieldes KJ. Whooping cough: Christchurch 1982. NZ Med J 1983;96:671-673
50. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med 1996;334:341-348
51. Salmaso S, Mastrantonio P, Tozzi AE, et al. Sustained Efficacy During the First 6 Years of Life of 3-Component Acellular Pertussis Vaccines Administered in Infancy: The Italian Experience. Pediatrics 2001;108:e81.
52. Anonymous. Immunisation coverage in New Zealand. Commun Dis NZ 1992;92(Suppl 2):1-13.
53. Lennon D, Jarman J, Jones N, et al. Immunisation coverage in North Health. Comparative results from North Health's 1996 immunisation coverage survey. Auckland: Northern Regional Health Authority, 1997.
54. Ministry of Health. The National Childhood Immunisation Coverage Survey 2005. Wellington: Ministry of Health, 2007.
55. Ministry of Health. Immunisation Handbook 2006. Wellington: Ministry of Health, 2006.
56. UNICEF. Progress for Children: A Report Card on Immunization (No.3). New York: UNICEF, 2005.
57. Craig E, Jackson C, Han DY, NZCYES Steering Committee. Monitoring the Health of New Zealand Children and Young People: Indicator Handbook. Auckland: Paediatric Society of New Zealand, New Zealand Child and Youth Epidemiology Service, 2007.
58. Ministry of Health. Immunisation Coverage National and DHB Data. Wellington: Ministry of Health, 2009.
59. Guyer B, Hughart N, Holt E, et al. Immunization coverage and its relationship to preventive health care visits among inner-city children in Baltimore. Pediatrics 1994;94:53-58 (Pubitemid 24194097)
60. Ministry of Health. National Immunisation Register. Wellington: Ministry of Health, 2007.
61. Grant CC, Turner NM, York DG, et al. Factors associated with immunisation coverage and timeliness in New Zealand. Br J Gen Pract 2010;60: e113-e120.
62. Miller JJ, Faber HK, Ryan ML, et al. Immunization against pertussis during the first 4 months of life. Pediatrics 1949;4:468-478
63. Provenzano RW, Wetterlow LH, Sullivan CL. Immunization and antibody response in the newborn infant. I. Pertussis inoculation within twenty-four hours of birth. N Engl J Med 1965;273:959-965
64. Grant CC, Roberts M, Scragg R, et al. Delayed immunisation and risk of pertussis in infants: unmatched case-control study. BMJ 2003;326:852-853 (Pubitemid 36461417)
65. Clark A, Sanderson C. Timing of children's vaccinations in 45 low-income and middleincome countries: an analysis of survey data. Lancet 2009;373:1543-1549
66. Rodewald LE, Szilagyi PG, Humiston SG, et al. A randomized study of tracking with outreach and provider prompting to improve immunization coverage and primary care. Pediatrics 1999;103:31-38
67. Ranganathan S, Tasker R, Booy R, et al. Pertussis is increasing in unimmunised infants: is a change in policy needed? Arch Dis Child 1999;80:297-299
68. Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 2006;118:978-984
69. Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005;353:1555-1563 (Pubitemid 41434634)
70. Hewlett EL, Edwards KM. Clinical practice. Pertussis - not just for kids. N Engl J Med 2005;352:1215-1222
71. Plotkin S. Aims, scope and findings of the global pertussis initiative. Pediatr Infect Dis J 2005;24:S5-6.
72. Forsyth KD, Campins-Marti M, Caro J, et al. New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis 2004;39:1802-1809 (Pubitemid 39657260)
73. Ministry of Health. Health Targets: Health Targets 2009/10. Wellington: Ministry of Health, 2009.
74. Hethcote HW. Simulations of pertussis epidemiology in the United States: effects of adult booster vaccinations. Math Biosci 1999;158:47-73.
75. Grant C, Petousis-Harris H, Turner N, et al. General practice and health professional determinants of immunisation coverage: report to the Ministry of Health and Health Research Council Immunisation Research Strategy. Auckland: University of Auckland, 2007.
76. Somerville RL, Grant CC, Grimwood K, et al. Infants hospitalised with pertussis: estimating the true disease burden. J Paediatr Child Health 2007;43:617-622 (Pubitemid 47222695)
77. Statistics New Zealand. What is the extent of crowding in New Zealand? An analysis of crowding in New Zealand households 1986-2001. Wellington: Statistics New Zealand, 2003.
78. Ministry of Social Development. 2009 The Social Report. Wellington: Ministry of Social Development, 2009.
79. Hart JT. The inverse care law. Lancet 1971;1:405-412
80. Anonymous. Strategies to sustain success in childhood immunizations. The National Vaccine Advisory Committee. JAMA 1999;282:363-370
81. Murphy TV, Slade BA, Broder KR, et al. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2008;Recommendations & Reports. 57:1-51.
82. Food and Drug Administration. Prescribing information. BOOSTRIX® (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed). Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, 2005.
83. Pichichero ME, Casey JR. Acellular pertussis vaccines for adolescents. Pediatr Infect Dis J 2005;24:S117-26.
84. Schmitt HJ, von Konig CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996;275:37-41. (Pubitemid 26004253)
85. De Serres G, Shadmani R, Duval B, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000;182:174-179
86. Bonacorsi S, Farnoux C, Bidet P, et al. Treatment failure of nosocomial pertussis infection in a very-low-birth-weight neonate. J Clin Microbiol 2006;44:3830-3832 (Pubitemid 46768831)
87. Baggett HC, Duchin JS, Shelton W, et al. Two nosocomial pertussis outbreaks and their associated costs - King County, Washington, 2004. Infect Cont Hosp Epidemiol 2007;28:537-543
88. Calugar A, Ortega-Sanchez IR, Tiwari T, et al. Nosocomial Pertussis: Costs of an Outbreak and Benefits of Vaccinating Health Care Workers. Clin Infect Dis 2006;42:981-988
89. Zivna I, Bergin D, Casavant J, et al. Impact of Bordetella pertussis exposures on a Massachusetts tertiary care medical system. Infect Cont Hosp Epidemiol 2007;28:708-712 (Pubitemid 46954758)
90. Paul S. NOVA The official staff newsletter of the Auckland District Health Board. Auckland: Auckland District Health Board, 2008.
91. Schellekens J, von Konig CH, Gardner P. Pertussis sources of infection and routes of transmission in the vaccination era. Pediatr Infect Dis J 2005;24:S19-24.
92. Elliott E, McIntyre P, Ridley G, et al. National study of infants hospitalized with pertussis in the acellular vaccine era. Pediatr Infect Dis J 2004;23:246-252 (Pubitemid 38332651)
93. Tanaka M, Vitek CR, Pascual FB, et al. Trends in pertussis among infants in the United States, 1980-1999. JAMA. 2003;290:2968-2975
94. Bramley D, Hebert P, Tuzzio L, Chassin M. Disparities in indigenous health: a cross-country comparison between New Zealand and the United States. Am J Public Health 2005;95:844-850 (Pubitemid 40593749)